A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROSPECT
- Sponsors Bavarian Nordic; BN ImmunoTherapeutics
- 12 Aug 2017 Planned End Date changed from 1 Jan 2019 to 1 Nov 2019.
- 12 Aug 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Nov 2018.
- 09 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 Jan 2019.